Novo Nordisk NOVO.B-0.54%decrease; red down pointing triangle said it would take over a drug under development to treat rare blood and kidney disorders from Nasdaq-listed biopharmaceutical firm Omeros ...

Novo Nordisk is drawing divided views from Wall Street analysts. Some may be disappointed by the loss of market share to Eli Lilly. Three events could turn sentiment positive in the coming months. The ...

Novo Nordisk may be breaking Heartseed's heart. As part of a company-wide restructuring under new CEO Maziar Mike Doustdar, the big pharma has axed a cell therapy collaboration with Heartseed worth ...

Morgan Stanley analyst Thibault Boutherin pointed to slowing momentum in U.S. prescriptions for Novo's flagship GLP-1 drugs, the weight-loss treatment Wegovy and type 2 diabetes therapy Ozempic. He ...

Despite the difficulties Novo Nordisk's GLP-1 franchise has encountered due to Eli Lilly and manufacturers of compounded versions of semaglutide, demand for Wegovy remains strong. So, its sales ...

Novo Nordisk has earned important label expansions this year. The company's pipeline progress should lead to more regulatory wins. Regulatory changes in the U.S. could also benefit the drugmaker. The ...

Novo Nordisk plans to cut 9,000 jobs globally, including 5,000 in Denmark, to streamline operations and focus on growth. Increased competition in the GLP-1 medication market, with new oral and ...

Because of its size, the drugmaker has an outsize effect on the country. Now, as it sheds jobs, forecasts for Denmark’s growth are falling, too. By Eshe Nelson The success of Novo Nordisk, the ...

The entrance to one of Novo Nordisk’s two manufacturing facilities in Clayton, North Carolina on June 24, 2024. Brian Gordon [email protected] The Danish drugmaker Novo Nordisk announced ...

Novo Nordisk, the maker of popular weight-loss drugs Ozempic and Wegovy, announced it is laying off about 9,000 workers in an effort to “streamline operations.” The company made the announcement on ...

Novo Nordisk stands out as the best pharma stock, outperforming Eli Lilly in key areas. Novo’s higher profitability, stronger cash flow, and much lower valuation make it a more attractive investment ...